Delivery Order SPE2DB22D1017-SPE2DB25FG5SC
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Sumatriptan 6 mg/0.5ml auto-injectors with a ceiling value of $12,080.19. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded a $5,327.53 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Sumatriptan 6 mg/0.5 mL auto-injectors. The contract, with an ultimate completion date of September 12, 2025, represents a single delivery transaction under AmerisourceBergen's existing pharmaceutical supply framework with DLA. This delivery order was competitively awarded with no set-aside designation, reflecting the company's established...
- The Defense Logistics Agency awarded a delivery order valued at $2,271.97 to AmerisourceBergen Drug Corp for the supply of Sumatriptan 6 mg/0.5 mL auto-injectors. This competitive award, issued on August 4, 2025, with an ultimate completion date of August 5, 2025, represents a firm fixed price delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a $3,127.06 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Sumatriptan 6 mg/0.5 mL auto-injectors on September 12, 2025, with an ultimate completion date of September 15, 2025. This delivery order was competitively awarded with no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle. The product will be delivered to the company's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $6,873.81 delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Sumatriptan 6 mg/0.5 mL auto-injector units. This firm fixed-price delivery order, with an ultimate completion date of June 3, 2025, represents a non-set-aside competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX). The product will be delivered to the contractor's corporate office...
- The Defense Logistics Agency awarded a $2,412.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Sumatriptan 6 mg/0.5 mL auto-injectors. The contract, with an ultimate completion date of July 25, 2025, was awarded on July 24, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a small-value transaction within...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Sumatriptan 6 mg/0.5 mL auto-injectors valued at $2,652.22. This competitively awarded, firm fixed-price delivery order will be fulfilled from the contractor's Conshohocken, Pennsylvania facility, with an ultimate completion date of August 8, 2025. The award represents a routine pharmaceutical supply transaction under a non-set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $2,914.29 to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Sumatriptan 6 mg/0.5 mL auto-injectors. This competitive, firm fixed-price delivery order is scheduled for completion by August 6, 2025, with performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation and represents a single procurement action under the company's larger...
- The Defense Logistics Agency awarded a $4,951.35 delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Sumatriptan 6 mg/0.5 mL auto-injectors. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and requires completion by September 18, 2025. AmerisourceBergen Drug Corp will perform this work from its corporate headquarters in Conshohocken, Pennsylvania, where the company operates as a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a $2,422.85 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Sumatriptan 6 mg/0.5 mL auto-injectors. This firm fixed-price contract, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive award executed through the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FG5SCDelivery Order
The Defense Logistics Agency awarded a $3,763.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 24, 2025, for the supply of Sumatriptan 6 mg/0.5 mL auto-injector units. The contract, which is non-set-aside and competitively awarded, calls for performance completion by June 25, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a single-item pharmaceutical procurement supporting federal medical supply chain requirements. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value through December 2026. As a prime vendor on this comprehensive global pharmaceutical support vehicle, AmerisourceBergen supplies an extensive portfolio of pharmaceuticals and medical supplies to support military healthcare programs and other federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. The company's established position as a major pharmaceutical distributor has enabled consistent competitive success across DLA's medical procurement programs, which are transitioning toward a multi-award Pharmaceutical Prime Vendor Global Program Generation V structure across regional zones.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 6/24/25 |